tiprankstipranks
Advertisement
Advertisement

DFTX Stock Latest News

Definium Therapeutics Shareholders Approve All Annual Meeting Proposals
Company AnnouncementsDefinium Therapeutics Shareholders Approve All Annual Meeting Proposals
5d ago
8K
DFTX
Francois Brisebois Reiterates Buy on Definium Therapeutics, Lifts Price Target to $44 on De-Risked DT120 Opportunity in Anxiety and Depression
PremiumRatings
Francois Brisebois Reiterates Buy on Definium Therapeutics, Lifts Price Target to $44 on De-Risked DT120 Opportunity in Anxiety and Depression
13d ago
DFTX
Definium Therapeutics Nears Pivotal Earnings Call Tests
PremiumCompany Announcements
Definium Therapeutics Nears Pivotal Earnings Call Tests
29d ago
DFTX
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline
PremiumCompany Announcements
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline
30d ago
8K
DFTX
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
PremiumThe Fly
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
1M ago
ATAI
CMND
Definium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs
PremiumRatingsDefinium Therapeutics: Buy Rating Reiterated with Unchanged $70 Price Target on Robust Late-Stage DT120 Pipeline and De-Risked Phase 3 Programs
1M ago
DFTX
Analyst Reiterates Buy on Definium Therapeutics as Late-Stage MDD and GAD Trials Advance; $38 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Definium Therapeutics as Late-Stage MDD and GAD Trials Advance; $38 Price Target Maintained
1M ago
DFTX
Definium begins second Phase 3 trial for DT120
Premium
Company Announcements
Definium begins second Phase 3 trial for DT120
1M ago
8K
DFTX
Definium Therapeutics says first patient dosed in Ascend study
PremiumThe Fly
Definium Therapeutics says first patient dosed in Ascend study
1M ago
DFTX
Mind Medicine Inc. Nears Pivotal DT120 Data
PremiumCompany Announcements
Mind Medicine Inc. Nears Pivotal DT120 Data
1M ago
DFTX
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
PremiumThe Fly
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
1M ago
DFTX
Definium Therapeutics reports Q1 EPS (71c), consensus (49c)
PremiumThe Fly
Definium Therapeutics reports Q1 EPS (71c), consensus (49c)
1M ago
DFTX
Beyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade
PremiumMarket NewsBeyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade
2M ago
DFTX
MSOS
Definium Therapeutics (DFTX): Late-Stage DT120 Psychedelic Pipeline and Multiple Near-Term Catalysts Support Buy Rating and $61 Target
Premium
Ratings
Definium Therapeutics (DFTX): Late-Stage DT120 Psychedelic Pipeline and Multiple Near-Term Catalysts Support Buy Rating and $61 Target
2M ago
DFTX
3 Different Ways to Play the Rally in Psychedelic Stocks
Premium
Market News
3 Different Ways to Play the Rally in Psychedelic Stocks
2M ago
DFTX
NBIX
Psychedelic: Exclusive talk with biopharma company Definium
PremiumThe Fly
Psychedelic: Exclusive talk with biopharma company Definium
2M ago
DFTX
Definium Therapeutics price target raised to $40 from $25 at Oppenheimer
PremiumThe Fly
Definium Therapeutics price target raised to $40 from $25 at Oppenheimer
2M ago
DFTX
Definium Therapeutics: Strengthened Investment Case and Multi-Indication Upside Ahead of Key Phase 3 Readouts
PremiumRatings
Definium Therapeutics: Strengthened Investment Case and Multi-Indication Upside Ahead of Key Phase 3 Readouts
2M ago
DFTX
Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety
PremiumCompany Announcements
Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety
2M ago
8K
DFTX
Definium Therapeutics highlights advancement of DT120 ODT
PremiumThe FlyDefinium Therapeutics highlights advancement of DT120 ODT
2M ago
DFTX
Definium Therapeutics: Policy Tailwinds and Late-Stage Clinical Momentum Support Attractive Risk‑Reward and Higher $38 Price Target
Premium
Ratings
Definium Therapeutics: Policy Tailwinds and Late-Stage Clinical Momentum Support Attractive Risk‑Reward and Higher $38 Price Target
2M ago
DFTX
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
2M ago
AMD
DIA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >